Feedback / Questions
cabotamig (ARB202) - Arbele
https://www.prnewswire.com/news-releases/novel-t-cell-engager-cdh17-x-cd3-cabotamig-arb202-continues-to-explore-dosing-in-patients-with-advanced-gastrointestinal-cancers-302128499.html
Apr 26, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next